Immunotherapy Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
DTIL | F | Precision BioSciences, Inc. | -1.36 | |
ADAP | F | Adaptimmune Therapeutics plc | 6.26 | |
IMTX | F | Immatics N.V. | 4.93 | |
MRKR | F | Marker Therapeutics, Inc. | 5.52 | |
CDTX | F | Cidara Therapeutics, Inc. | 1.87 | |
THMO | F | ThermoGenesis Holdings, Inc. | 0.00 | |
TLSI | F | TriSalus Life Sciences, Inc. | 5.57 | |
INMB | F | INmune Bio Inc. | 3.02 | |
IPHA | F | Innate Pharma S.A. | -4.48 | |
FBIO | F | Fortress Biotech, Inc. | 1.24 |
Related Industries: Biotechnology Broadcasting - TV Diagnostics & Research Medical Care Medical Devices Other
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
EWK | C | iShares MSCI Belgium Capped Investable Market Index Fund | 6.71 | |
MNTL | F | Tema Neuroscience and Mental Health ETF | 4.79 | |
BBH | D | Market Vectors Biotech ETF | 4.41 | |
CANC | D | Tema Oncology ETF | 4.19 | |
FBT | A | First Trust Amex Biotech Index Fund | 3.61 |
Compare ETFs
- Immunotherapy
Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.
Popular Now
Recent Comments
- LillyMilly1 on LILM
- LillyMilly1 on LILM
- TraderMike on RYDE what a RIDE!!! Holy Crap!
- Crunching_The_Market on RYDE what a RIDE!!! Holy Crap!
- LillyMilly1 on LILM
From the Blog
Featured Articles